Glucagon · Baqsimi, Gvoke Hypopen 0.5 Mg Auto-Injector

What is Glucagon?

Glucagon is a recombinant peptide hormone that activates hepatic glucagon receptors to stimulate glycogen breakdown and glucose release from the liver, raising blood glucose concentration.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Baqsimi, Gvoke Hypopen 0.5 Mg Auto-Injector, Gvoke Vialdx, Novo Nordisk GlucaGen

Drug type

Recombinant protein

Targets

glucagon receptor (GCGR)

Mechanism

Agonist of glucagon receptor (GCGR)

Pathways

glycogen breakdown, glucose release

Therapy area

Endocrine

Developer

Lilly

In trials of

XERS

FDA status

Approved as Baqsimi, Gvoke Hypopen 0.5 Mg Auto-Injector, Gvoke Vialdx (November 14, 1960), NDA012122 · FDA label

✅ FDA-approved uses

• Severe hypoglycemia in adults and pediatric patients aged 1 year and older with diabetes (Baqsimi)
• Diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients (Gvoke Vialdx)

From the indications section of the FDA label (version of Jun 19, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetes Mellitus, Type 1HypoglycemiaInsulin HypoglycemiaSevere HypoglycemiaType 1 Diabetes Mellitus

Other drugs acting on GCGR

Sources

• FDA label (DailyMed)
• FDA label Gvoke Vialdx (2026-07-07), indications
• FDA label Baqsimi (2026-06-19), indications
• FDA label Gvoke Hypopen 0.5 Mg Auto-Injector (2025-12-23), indications
• FDA label Glucagon (2025-03-31), indications
• ClinicalTrials.gov NCT02081001
• ClinicalTrials.gov NCT02411578
• ClinicalTrials.gov NCT03439072
• ClinicalTrials.gov NCT03439072

Updated Oct 3, 2026.